SERA Stock Summary and Trading Ideas (Sera Prognostics - Class A | NASDAQ:SERA)

Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services.

Sera Prognostics - Class A trades on the NASDAQ stock market under the symbol SERA.

As of May 8, 2024, SERA stock price declined to $9.30 with 94,520 million shares trading.

SERA has a beta of 1.47, meaning it tends to be more sensitive to market movements. SERA has a correlation of 0.03 to the broad based SPY ETF.

SERA has a market cap of $303.56 million. This is considered a Small Cap stock.

Last quarter Sera Prognostics - Class A reported $41,000 in Revenue and -$.25 earnings per share. This fell short of revenue expectation by $-9,000 and exceeded earnings estimates by $.01.

The top ETF exchange traded funds that SERA belongs to (by Net Assets): DWAS, VTI, VXF, IWC, AVSC.

SERA has outperformed the market in the last year with a return of +160.5%, while the SPY ETF gained +27.0%. In the last 3 month period, SERA beat the market returning +17.4%, while SPY returned +4.2%. However, in the most recent 2 weeks SERA has underperformed the stock market by returning -6.6%, while SPY returned +2.3%.

SERA support price is $8.89 and resistance is $10.07 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SERA stock will trade within this expected range on the day.